Poly-L-Lactic Acid Attenuates Fibrotic Remodeling During Cutaneous Wound Healing
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27198874 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Kyung-A Byun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy & Cell Biology, College of Medicine, Gachon University, Incheon 21936, Republic of Korea. Hauptthemen laut MEDLINE: Wound Healing, Polyesters, Skin. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LIBON Inc., Gachon University.
Themen: Wundversorgung
Abstract (Originalsprache)
Pathological hypoxia following cutaneous injury is a critical driver of wound chronicity and fibrotic remodeling. The nuclear receptor binding SET domain protein 2 (NSD2)/lysine demethylase 2A (KDM2A)–histone H3 lysine 36 dimethylation (H3K36me2) axis is a known regulator of hypoxia-induced epithelial-to-mesenchymal transition (EMT) in malignancy; however, its role in skin repair remains largely unexplored. We investigated whether poly-L-lactic acid (PLLA) could attenuate fibrotic remodeling by modulating the NSD2/KDM2A–H3K36me2 axis and examining angiogenic signaling. We used a murine 9 mm punch-wound model for in vivo assessment and HaCaT keratinocytes and human dermal fibroblasts (HDFs) exposed to 2% O2 as in vitro hypoxia models. PLLA was administered to evaluate its impact on angiogenic signaling, collagen architecture, and the NSD2/KDM2A pathway. PLLA was associated with increased angiogenic markers and reduced expression of several hypoxia-associated epigenetic and fibrotic markers. In mice, PLLA increased vascular endothelial growth factor (VEGF)/VEGF receptor 2 expression and blood vessel abundance. In addition, PLLA decreased NSD2 and H3K36me2 levels while increasing KDM2A levels. Histological analysis showed less dense collagen staining and a change in the collagen type I/type III staining ratio, alongside a smaller photographically defined residual lesion area. Under controlled hypoxic conditions in vitro, PLLA suppressed EMT-related transcription factors, including Snail, Slug, and Twist, in keratinocytes and attenuated transforming growth factor-β1/phosphorylated mothers against decapentaplegic homolog 2/3 signaling and α-smooth muscle actin expression in fibroblasts. These findings support further study of PLLA-associated changes in vascular, epithelial, and fibrotic markers during wound remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy & Cell Biology, College of Medicine, Gachon University, Incheon 21936, Republic of Korea.
- Functional Cellular Networks Laboratory, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, Republic of Korea.
- LIBON Inc., Incheon 22006, Republic of Korea.
- Maylin Apgujeong Clinic, Seoul 06024, Republic of Korea.
- Maylin Clinic Jamsil Lotte Hotel Branch, Seoul 05554, Republic of Korea.
- Director Global Clinic Gangnam, Seoul 06611, Republic of Korea.
ORCID-Profile: Kyung-A Byun, Hyoung Moon Kim, Kuk Hui Son, Kyunghee Byun
Förderung
- LIBON Inc.
- Gachon University
Zitieren
APA
Byun, K. A., Kim, H. M., Oh, S., Yu, K. W., Lee, J. M., Son, K. H., & Byun, K. (2026). Poly-L-Lactic Acid Attenuates Fibrotic Remodeling During Cutaneous Wound Healing. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198874
Vancouver
Byun KA, Kim HM, Oh S, Yu KW, Lee JM, Son KH, et al. Poly-L-Lactic Acid Attenuates Fibrotic Remodeling During Cutaneous Wound Healing. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198874
BibTeX
@article{Byun2026,
author = {Byun, Kyung-A and Kim, Hyoung Moon and Oh, Seyeon and Yu, Ki Woong and Lee, Ji Min and Son, Kuk Hui and Byun, Kyunghee},
title = {Poly-L-Lactic Acid Attenuates Fibrotic Remodeling During Cutaneous Wound Healing},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27198874}
}
EUVIMED